open access

Vol 7, No 1-2 (2001)
Original papers
Published online: 2001-10-18
Get Citation

Tissue factor pathway inhibitor (TFPI) in patients with occlusive arterial diseases in consideration with risk factors and conservative treatment of the disease

Piotr Radziwon, Michał Bielawiec, Janusz Kłoczko, Jan Giedrojć, Katarzyna Mazgajska, Marzenna Galar, Marzenna Klimiuk
Acta Angiologica 2001;7(1-2):43-54.

open access

Vol 7, No 1-2 (2001)
Original papers
Published online: 2001-10-18

Abstract

The aim of the study was to determine the level of tissue factor pathway inhibitor (TFPI) in patients with arterial occlusive diseases of the lower limbs and to consider correlation of TFPI with some risk factors of the development of these diseases: cigarette smoking, hyperlipidaemia and age. The effect of conservative treatment with pentoxifylline and alprostadil of the peripheral arterial occlusive disease (PAOD) on plasma concentration of TFPI was also investigated. TFPI concentration was not dependent on the age of healthy per sons. Patients with PAOD or Buerger`s disease showed elevated concentrations of TFPI compared to healthy adults without any symptoms of the arterial disease, 333.3 ± 100.2 ng/mL, 177.9 ± 67.1 ng/mL, 95.7 ± ± 25.3 ng/mL respectively. There are no significant differences of TFPI concentration in smokers, former smokers and non-smokers in the group of healthy persons. Conservative treatment of PAOD with pentoxifylline or alprostadil had no effect on TFPI concentration in patients with PAOD. The results of the study suggest, that the elevated TFPI concentration in patients with arterial occlusive diseases mainly depends on state of the vascular endothelium.

Abstract

The aim of the study was to determine the level of tissue factor pathway inhibitor (TFPI) in patients with arterial occlusive diseases of the lower limbs and to consider correlation of TFPI with some risk factors of the development of these diseases: cigarette smoking, hyperlipidaemia and age. The effect of conservative treatment with pentoxifylline and alprostadil of the peripheral arterial occlusive disease (PAOD) on plasma concentration of TFPI was also investigated. TFPI concentration was not dependent on the age of healthy per sons. Patients with PAOD or Buerger`s disease showed elevated concentrations of TFPI compared to healthy adults without any symptoms of the arterial disease, 333.3 ± 100.2 ng/mL, 177.9 ± 67.1 ng/mL, 95.7 ± ± 25.3 ng/mL respectively. There are no significant differences of TFPI concentration in smokers, former smokers and non-smokers in the group of healthy persons. Conservative treatment of PAOD with pentoxifylline or alprostadil had no effect on TFPI concentration in patients with PAOD. The results of the study suggest, that the elevated TFPI concentration in patients with arterial occlusive diseases mainly depends on state of the vascular endothelium.
Citation Formats

Keywords

TF; TFPI; atherosclerosis; Buerger' s disease

About this article
Title

Tissue factor pathway inhibitor (TFPI) in patients with occlusive arterial diseases in consideration with risk factors and conservative treatment of the disease

Journal

Acta Angiologica

Issue

Vol 7, No 1-2 (2001)

Pages

43-54

Published online

2001-10-18

Bibliographic record

Acta Angiologica 2001;7(1-2):43-54.

Keywords

TF
TFPI
atherosclerosis
Buerger's disease

Authors

Piotr Radziwon
Michał Bielawiec
Janusz Kłoczko
Jan Giedrojć
Katarzyna Mazgajska
Marzenna Galar
Marzenna Klimiuk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl